BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32109195)

  • 1. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.
    McHugh DJ; Funt SA; Silber D; Knezevic A; Patil S; O'Donnell D; Tsai S; Reuter VE; Sheinfeld J; Carver BS; Motzer RJ; Bajorin DF; Bosl GJ; Feldman DR
    J Clin Oncol; 2020 Apr; 38(12):1332-1337. PubMed ID: 32109195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
    J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
    Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
    Tachibana I; Kern SQ; Douglawi A; Tong Y; Mahmoud M; Masterson TA; Adra N; Foster RS; Einhorn LH; Cary C
    J Clin Oncol; 2022 Nov; 40(32):3762-3769. PubMed ID: 35675585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
    Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
    J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Sheinfeld J
    Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
    Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
    Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.
    Funt SA; McHugh DJ; Tsai S; Knezevic A; O'Donnell D; Patil S; Silber D; Bromberg M; Carousso M; Reuter VE; Carver BS; Sheinfeld J; Motzer RJ; Bajorin DF; Bosl GJ; Feldman DR
    Oncologist; 2021 Jun; 26(6):483-491. PubMed ID: 33586274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.
    Hiester A; Fingerhut A; Niegisch G; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Loy V; Wittekind C; Hartmann M; Albers P
    Eur J Cancer; 2021 Sep; 155():64-72. PubMed ID: 34371444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
    Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Modified retroperitoneal lymphadenectomy in non-seminomatous stage I, IIa and IIb testicular tumors].
    Sparwasser C; Treiber U; Beckert R; Pust RA
    Urologe A; 1995 Nov; 34(6):444-8. PubMed ID: 8848854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy for stage II nonseminomatous testicular cancer: what is its role?
    Motzer RJ
    Semin Urol Oncol; 1996 Feb; 14(1):30-3. PubMed ID: 8833386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.
    Tong S; Chen M; Zu X; Li Y; He W; Lei Y; Liu W; Qi L
    Int Urol Nephrol; 2014 Feb; 46(2):363-9. PubMed ID: 23996573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
    J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors.
    Kondagunta GV; Motzer RJ
    Semin Urol Oncol; 2002 Nov; 20(4):239-43. PubMed ID: 12489056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.